Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Catheter Equipment

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1744904

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1744904

Transarterial Chemoembolization

PUBLISHED:
PAGES: 375 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Transarterial Chemoembolization Market to Reach US$21.8 Billion by 2030

The global market for Transarterial Chemoembolization estimated at US$16.8 Billion in the year 2024, is expected to reach US$21.8 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Chemotherapeutic Agents, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$11.5 Billion by the end of the analysis period. Growth in the Radio Therapeutic Agents segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.6 Billion While China is Forecast to Grow at 8.1% CAGR

The Transarterial Chemoembolization market in the U.S. is estimated at US$4.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global "Transarterial Chemoembolization" Market - Key Trends & Drivers Summarized

Why Is Transarterial Chemoembolization Becoming a Standard for Liver Cancer Treatment Worldwide?

Transarterial chemoembolization (TACE) has emerged as a preferred and increasingly standardized therapy for intermediate-stage hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Unlike systemic chemotherapy, TACE delivers high-dose chemotherapy directly into the hepatic artery feeding the tumor while simultaneously blocking the blood supply, leading to targeted drug exposure and localized tumor necrosis. This dual mechanism has proven particularly effective in patients ineligible for surgical resection or liver transplantation. TACE is also being adopted as a bridging therapy for patients awaiting transplantation, helping to stabilize disease progression. Globally, the incidence of liver cancer is rising due to factors such as chronic hepatitis B and C infections, non-alcoholic fatty liver disease (NAFLD), and alcohol-related liver damage. These trends have increased demand for locoregional therapies like TACE, which offer improved survival rates and disease control with a lower systemic toxicity profile. Emerging guidelines by international oncology societies are endorsing TACE as a frontline or combination treatment for liver malignancies, thereby reinforcing its central role in therapeutic pathways and boosting adoption among healthcare providers worldwide.

How Are Drug Delivery Innovations and Imaging Technologies Enhancing TACE Outcomes?

The effectiveness of TACE has significantly improved through advancements in embolic materials, catheter technology, and imaging guidance systems. Drug-eluting beads (DEBs), which allow for controlled and sustained release of chemotherapy agents at the tumor site, have largely replaced traditional lipiodol-based formulations in many markets, reducing systemic exposure and improving response rates. Technological enhancements in microcatheters and steerable delivery systems have made it possible to navigate complex vascular anatomies with precision, minimizing damage to healthy liver tissue. At the same time, real-time imaging modalities such as cone-beam CT and 3D angiography have revolutionized intra-procedural visualization, allowing for highly targeted delivery and immediate verification of treatment success. These innovations have also paved the way for personalized treatment plans, where tumor size, location, and vascularity are factored into decisions on embolic type, particle size, and dosing schedules. Additionally, the integration of AI in imaging analytics is beginning to assist interventional radiologists in pre-procedural planning and post-procedural outcome assessments, improving consistency and long-term prognoses. These technology-led improvements are not only boosting clinical outcomes but also expanding the candidate pool for TACE.

Is the Global Healthcare Landscape Ready for the Widespread Adoption of TACE?

The global healthcare ecosystem is increasingly receptive to the widespread adoption of transarterial chemoembolization, supported by expanding interventional radiology infrastructure and a growing base of trained specialists. In high-income countries, the presence of sophisticated imaging suites, multidisciplinary tumor boards, and dedicated oncology pathways has allowed for the seamless integration of TACE into liver cancer care algorithms. Meanwhile, middle-income countries are investing heavily in minimally invasive cancer care, recognizing TACE’s value in resource-constrained settings where access to advanced surgery or systemic therapies is limited. In Asia-Pacific, where liver cancer incidence is particularly high, governments are including TACE in public insurance schemes and national cancer control programs, fueling rapid market expansion. Private sector investments in ambulatory surgical centers and oncology-focused hospitals are also contributing to the increased availability of TACE in urban and peri-urban regions. However, challenges remain in low-income countries due to inadequate imaging capabilities and a shortage of skilled interventional radiologists. Efforts by global health organizations to improve access through mobile IR units, training programs, and public-private partnerships are beginning to address these disparities, gradually democratizing access to this life-extending procedure.

The Growth in the Transarterial Chemoembolization Market Is Driven by Several Factors…

The growth in the transarterial chemoembolization market is driven by several factors rooted in disease prevalence, medical innovation, and healthcare system evolution. A primary driver is the rising global burden of liver cancer, fueled by aging populations, viral hepatitis, alcohol consumption, and metabolic disorders. As patient volumes increase, so does the need for intermediate therapies like TACE that fill the treatment gap between curative and palliative care. From a technological perspective, the development of next-generation embolic agents, improved catheter navigation tools, and AI-powered imaging analytics is enhancing procedural efficacy and safety. Healthcare providers are embracing TACE for its minimally invasive profile, shorter recovery times, and lower complication rates compared to systemic chemotherapy or surgery. Additionally, the growing preference for outpatient interventional oncology treatments is expanding demand for TACE in both hospital and specialty clinic settings. Insurance reimbursements, particularly in developed and rapidly developing economies, are being streamlined to cover TACE as a first-line therapy, increasing patient access. Strategic collaborations between device manufacturers, pharma companies, and interventional radiology networks are also fostering innovation and market penetration. Collectively, these factors are positioning TACE as a vital pillar in the multidisciplinary management of liver cancer worldwide.

SCOPE OF STUDY:

The report analyzes the Transarterial Chemoembolization market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Chemotherapeutic Agents, Radio Therapeutic Agents, Drug-Eluting Particles); Indication (Unresectable HCC, Early-Stage HCC); End-Use (Hospitals, Clinics, Cancer Research Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Advaxis Inc.
  • Bayer AG
  • Bellicum Pharmaceuticals
  • Boston Scientific Corporation
  • CELGENE Corporation
  • Cook Medical
  • F. Hoffmann-La Roche Ltd
  • Hikma Pharmaceuticals PLC
  • Isofol Medical AB
  • Kaneka Corporation
  • Medtronic plc
  • Merck & Co., Inc.
  • Merit Medical Systems, Inc.
  • Nippon Kayaku Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Siemens Healthineers AG
  • Sirtex Medical Limited
  • Spectrum Pharmaceuticals, Inc.
  • Terumo Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP35900

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Transarterial Chemoembolization - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Liver Cancer and Hepatocellular Carcinoma Propels Demand for TACE Procedures
    • Increasing Preference for Minimally Invasive Oncology Treatments Expands TACE Adoption
    • Advancements in Drug-Eluting Beads Technology Strengthen Clinical Outcomes and Market Appeal
    • Expanding Use of TACE in Palliative Cancer Care Throws the Spotlight on Targeted Therapies
    • Growing Acceptance of TACE as a First-Line Treatment Drives Procedural Volumes Globally
    • Integration of Imaging Guidance Systems Enhances Precision and Spurs Market Innovation
    • Favorable Reimbursement Scenarios in Developed Markets Support Wider Procedural Uptake
    • Aging Population and Comorbidities Increase Patient Pool for Non-Surgical Therapies
    • Expansion of Interventional Radiology Infrastructure in Emerging Markets Sustains Global Growth
    • Improved Catheterization Techniques Propel Success Rates and Professional Confidence in TACE
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Transarterial Chemoembolization Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Transarterial Chemoembolization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Chemotherapeutic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Radio Therapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Radio Therapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Radio Therapeutic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Drug-Eluting Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Drug-Eluting Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Drug-Eluting Particles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Unresectable HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Unresectable HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Unresectable HCC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Early-Stage HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Early-Stage HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Early-Stage HCC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cancer Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cancer Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Cancer Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Transarterial Chemoembolization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Transarterial Chemoembolization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Transarterial Chemoembolization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Transarterial Chemoembolization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!